INCRUSE ELLIPTA 62.5 MCG INH

What it is

INCRUSE ELLIPTA 62.5 MCG INH is how the CMS NADAC file names this product. The FDA NDC Directory lists it as umeclidinium, under the trade name “Incruse Ellipta”.

FDA gives its dosage form as aerosol, powder and its route as oral.

The labeler, the company named on the label, is GlaxoSmithKline LLC.

FDA’s Established Pharmacologic Class for it is Anticholinergic.

The NADAC file of 2026-10-14 prices it under 2 NDCs (National Drug Codes).

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $10.28 – $11.30 for 1 unit (EA), depending on the NDC ($10.27714 to $11.29916 per EA), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 5, calculated based on package size.

NADAC also lists, on the row of one brand NDC, what pharmacies pay for the generic equivalent, a different product: $7.35063 per EA filed.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

What NADAC measures · NADAC explanation codes

All 2 NDCs

• 00173-0873-06 · GlaxoSmithKline LLC · $10.27714 per EA · eff. 2026-09-23 filed
• 00173-0873-10 · GlaxoSmithKline LLC · $11.29916 per EA · eff. 2026-09-23 filed

Other strengths, forms and brands

1 other product in the NADAC file shares the FDA nonproprietary name umeclidinium with INCRUSE ELLIPTA 62.5 MCG INH.

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

The middle of its 2 NDCs’ NADAC prices is $10.27714 per EA filed.

Of the 23 other products in FDA’s Anticholinergic class priced per EA, 6 have a higher middle NADAC price and 17 a lower one. The one in the middle is LOMOTIL 2.5-0.025 MG TABLET, at $2.99096 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part D paid $11.36 for 1 unit (EA), at an average of $11.35773 per EA in 2024 (2024-01-01 to 2024-12-31) for “Incruse Ellipta” and “Umeclidinium Bromide”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 852,329 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 1 unit (EA)? Is it lower than what I would pay through my insurance?
• Which NDC (the 11-digit number on the package) is this? Pharmacies pay $10.27714 to $11.29916 per EA for this product, depending on the NDC.
• Is a generic version available, and would it suit me? NADAC lists a generic with the same ingredient, strength and dosage form by FDA: UMECLIDINIUM ELLIPTA 62.5 MCG INH. Ask your pharmacist or prescriber; do not switch on your own.
• If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.